---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-140755"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:44:15.037726+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population

## Summary
- Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.
- Cash and equivalents $223.8M as of March 31; runway projected into Q1 2025.
- Phase 3 VGX-3100 for cervical HSIL missed primary endpoint in biomarker population but achieved statistical significance in all-participants.
- INO-3107 for RRP: 10 of 11 (91%) patients saw reduction in surgical interventions; well-tolerated.
- Appointed Dr. Cheryl Elder as SVP Regulatory Affairs.

## SEC filing metadata
- accession: 0001193125-23-140755
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/0001193125-23-140755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/d425606d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-140755
- JSON: https://secwatch.observer/filing/0001193125-23-140755.json
- Plain text: https://secwatch.observer/filing/0001193125-23-140755.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 10, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/0001193125-23-140755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.